

## **Patient Diary**

Please use this diary to record the date, lot numbers, and reason for injection each time you inject Cinryze (Human C1-esterase inhibitor) and share this information with your treating physician at your next visit.

Online Guide to Self-Administration of Cinryze
To support administration training with Cinryze, an online
patient guide is available at:
pwa.ltd/Cinryze-pat-uk

If you are a new user you have to set up a user name and password which is needed each time you log-on to the tool. This tool provides:

- · A graphical guide to using Cinryze,
- Questionnaires to help you remember the key steps in preparing and using Cinryze and
- Downloadable documents including additional copies of this Patient Diary.

## Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.

Date of injection	Time of injection	Vial lot numbers	Expiry date(s)	Reason for injection	Dose Received	Response to Treatment	Adverse Reactions
				☐ Treatment of attack☐ Routine prevention☐ Pre-procedure			
				☐ Treatment of attack☐ Routine prevention☐ Pre-procedure			
				☐ Treatment of attack ☐ Routine prevention ☐ Pre-procedure			
				☐ Treatment of attack ☐ Routine prevention ☐ Pre-procedure			
				☐ Treatment of attack ☐ Routine prevention ☐ Pre-procedure			
				☐ Treatment of attack ☐ Routine prevention ☐ Pre-procedure			
				☐ Treatment of attack ☐ Routine prevention ☐ Pre-procedure			
				☐ Treatment of attack ☐ Routine prevention ☐ Pre-procedure			
				☐ Treatment of attack ☐ Routine prevention ☐ Pre-procedure			
				☐ Treatment of attack ☐ Routine prevention ☐ Pre-procedure			
				☐ Treatment of attack ☐ Routine prevention ☐ Pre-procedure			
				☐ Treatment of attack ☐ Routine prevention ☐ Pre-procedure			

<sup>▼</sup> This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects. Alternatively side effects should be reported to Takeda UK Ltd on 03333 000181 or via AE.GBR-IRL@takeda.com

June 2023 MHRA approval date: July 2023